Sökning: id:"swepub:oai:gup.ub.gu.se/303554" >
Brain-derived neuro...
Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington's disease.
-
Ou, Zhen-Yi Andy (författare)
-
Byrne, Lauren M (författare)
-
Rodrigues, Filipe B (författare)
-
visa fler...
-
Tortelli, Rosanna (författare)
-
Johnson, Eileanoir B (författare)
-
Foiani, Martha S (författare)
-
Arridge, Marzena (författare)
-
De Vita, Enrico (författare)
-
Scahill, Rachael I (författare)
-
Heslegrave, Amanda (författare)
-
- Zetterberg, Henrik, 1973 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
Wild, Edward J (författare)
-
visa färre...
-
(creator_code:org_t)
- 2021-02-10
- 2021
- Engelska.
-
Ingår i: Scientific reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 11:1
- Relaterad länk:
-
https://www.nature.c...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Brain-derived neurotrophic factor (BDNF) is implicated in the survival of striatal neurons. BDNF function is reduced in Huntington's disease (HD), possibly because mutant huntingtin impairs its cortico-striatal transport, contributing to striatal neurodegeneration. The BDNF trophic pathway is a therapeutic target, and blood BDNF has been suggested as a potential biomarker for HD, but BDNF has not been quantified in cerebrospinal fluid (CSF) in HD. We quantified BDNF in CSF and plasma in the HD-CSF cohort (20 pre-manifest and 40 manifest HD mutation carriers and 20 age and gender-matched controls) using conventional ELISAs and an ultra-sensitive immunoassay. BDNF concentration was below the limit of detection of the conventional ELISAs, raising doubt about previous CSF reports in neurodegeneration. Using the ultra-sensitive method, BDNF concentration was quantifiable in all samples but did not differ between controls and HD mutation carriers in CSF or plasma, was not associated with clinical scores or MRI brain volumetric measures, and had poor ability to discriminate controls from HD mutation carriers, and premanifest from manifest HD. We conclude that BDNF in CSF and plasma is unlikely to be a biomarker of HD progression and urge caution in interpreting studies where conventional ELISA was used to quantify CSF BDNF.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Ou, Zhen-Yi Andy
-
Byrne, Lauren M
-
Rodrigues, Filip ...
-
Tortelli, Rosann ...
-
Johnson, Eileano ...
-
Foiani, Martha S
-
visa fler...
-
Arridge, Marzena
-
De Vita, Enrico
-
Scahill, Rachael ...
-
Heslegrave, Aman ...
-
Zetterberg, Henr ...
-
Wild, Edward J
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Neurovetenskaper
- Artiklar i publikationen
-
Scientific repor ...
- Av lärosätet
-
Göteborgs universitet